Mobile

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-005103-18

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in stable CHD patients, with a documented recent ACS.

Critère d'inclusion

  • Stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)

Liens